|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/08 | (2006.01) |
| A61K 8/64 | (2013.01) | ||
| A61K 8/64 | (2006.01) | ||
| A61K2800/92 | (2013.01) | ||
| A61P 17/10 | (2006.01) | ||
| A61Q 19/08 | (2013.01) | ||
| A61P 1/00 | (2006.01) | ||
| A61P 9/14 | (2018.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 11/02 | (2018.01) | ||
| A61P 13/10 | (2018.01) | ||
| A61P 17/02 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61M 5/178 | (2006.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 25/02 | (2018.01) | ||
| A61Q 19/08 | (2006.01) | ||
| A61P 25/04 | (2018.01) | ||
| A61P 25/14 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 37/08 | (2018.01) | ||
| A61P 1/00 | (2018.01) | ||
| A61P 17/02 | (2018.01) | ||
| A61P 17/10 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 37/00 | (2018.01) | ||
| C12Y 304/24069 | (2013.01) |
| (11) | Number of the document | 3368071 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16860952.7 |
| Date of filing the European patent application | 2016-10-28 | |
| (97) | Date of publication of the European application | 2018-09-05 |
| (45) | Date of publication and mention of the grant of the patent | 2022-01-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/059492 |
| Date | 2016-10-28 |
| (87) | Number | WO 2017/075468 |
| Date | 2017-05-04 |
| (30) | Number | Date | Country code |
| 201562248255 P | 2015-10-29 | US |
| (72) |
RUEGG, Curtis L. , US
WAUGH, Jacob M. , US
|
| (73) |
ReVance Therapeutics, Inc. ,
7555 Gateway Blvd., Newark, CA 94560,
US
|
| (54) | INJECTABLE BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THEREOF HAVING LONG DURATION OF THERAPEUTIC OR COSMETIC EFFECT |
| INJECTABLE BOTULINUM TOXIN FORMULATIONS AND METHODS OF USE THEREOF HAVING LONG DURATION OF THERAPEUTIC OR COSMETIC EFFECT |